ArticleArrhythmia & electrophysiology review2026
Radiofrequency Catheter Ablation for Arrhythmia-induced Cardiomyopathy in Infants: A Case Series and Literature Review.
Article in Arrhythmia & electrophysiology review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiofrequency catheter ablation (RFCA) is an established treatment for paediatric arrhythmias in children weighing >15 kg, yet its role in infants with arrhythmia-induced cardiomyopathy remains less defined. This case series evaluates the efficacy and safety of RFCA in four infants (aged ≤1 year) with arrhythmia-induced cardiomyopathy through a retrospective review of clinical profiles, procedural data and outcomes. All patients had right-sided accessory pathways, with three showing atrioventricular re-entrant tachycardia and one pre-excitation-related cardiomyopathy. Each infant had failed pharmacotherapy, and presented with heart failure and cardiac enlargement. RFCA was successfully performed in all cases without complications. Within 1-6 months postprocedure, both cardiac function and size normalised in every patient. These findings support RFCA as a safe and effective treatment for medically refractory, right-sided, pathway-mediated, arrhythmia-induced cardiomyopathy in infants, highlighting its potential for complete functional recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.